Close Menu
Money MechanicsMoney Mechanics
    What's Hot

    NSYNC’s Joey Fatone Had to Auction His House to Avoid Bankruptcy

    April 15, 2026

    Nasdaq Up 455 Points for 10th Straight Win: Stock Market Today

    April 15, 2026

    The Top AI Apps Consumers Are Actually Using

    April 14, 2026
    Facebook X (Twitter) Instagram
    Trending
    • NSYNC’s Joey Fatone Had to Auction His House to Avoid Bankruptcy
    • Nasdaq Up 455 Points for 10th Straight Win: Stock Market Today
    • The Top AI Apps Consumers Are Actually Using
    • Wall Street banks break records as Iran war drives trading boom
    • Ben Cowan: Is the Fed Heading Toward Checkmate?
    • Tired of Gemini interrupting you? This Google Home update fixes that and more
    • Africa back in play – Oil & Gas 360
    • Real Estate ‘Finfluencer’ Tyler Bossetti Is Sentenced in Ponzi Scam
    Facebook X (Twitter) Instagram
    Money MechanicsMoney Mechanics
    • Home
    • Markets
      • Stocks
      • Crypto
      • Bonds
      • Commodities
    • Economy
      • Fed & Rates
      • Housing & Jobs
      • Inflation
    • Earnings
      • Banks
      • Energy
      • Healthcare
      • IPOs
      • Tech
    • Investing
      • ETFs
      • Long-Term
      • Options
    • Finance
      • Budgeting
      • Credit & Debt
      • Real Estate
      • Retirement
      • Taxes
    • Opinion
    • Guides
    • Tools
    • Resources
    Money MechanicsMoney Mechanics
    Home»Markets»Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration
    Markets

    Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration

    Money MechanicsBy Money MechanicsApril 14, 2026No Comments2 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Gilead Sciences Inc. (NASDAQ:GILD) is one of the 8 Best Quality Stocks to Buy According to Hedge Funds. Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality stocks to buy according to hedge funds. On April 9, Tempus AI (NASDAQ:TEM) announced an expanded, multi-year collaboration with Gilead Sciences to accelerate Gilead’s oncology research and development pipeline. The agreement builds on previous work where Gilead utilized Tempus’ de-identified multimodal data for trial design, biomarker strategies, and health outcomes analysis.

    Under this new enterprise-wide mandate, Gilead gains broader access to Tempus’ AI-driven Lens platform and dedicated analytical services across multiple cancer indications. The partnership aims to use Tempus’ vast library of real-world data to uncover biological insights that can improve clinical decision-making.

    By integrating Gilead’s scientific expertise with advanced data insights, the companies seek to increase the probability of success for new cancer therapies. Patrick Loerch, SVP of Clinical Data Science at Gilead Sciences Inc. (NASDAQ:GILD), emphasized that the collaboration focuses on putting patients at the center of innovation through data-informed research. The collaboration underscores the growing role of AI and real-world evidence in modern drug development and precision medicine.

    Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration
    Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration

    Copyright: dolgachov / 123RF Stock Photo

    Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

    Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.

    While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

    Disclosure: None. Follow Insider Monkey on Google News.



    Source link

    AI stock Gilead Sciences multimodal data Tempus AI Tempus AI Inc
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleU.S. natural gas consumption set a monthly and yearly record in 2025
    Next Article Historic Connecticut Mills To Become New Housing After 15-Year Wait
    Money Mechanics
    • Website

    Related Posts

    Wall Street banks break records as Iran war drives trading boom

    April 14, 2026

    Only One of These Energy Dividends Is Safe to Hold Forever

    April 14, 2026

    The Energy Report: Trump’s Blockade Turns Bearish for Oil

    April 14, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    NSYNC’s Joey Fatone Had to Auction His House to Avoid Bankruptcy

    April 15, 2026

    Nasdaq Up 455 Points for 10th Straight Win: Stock Market Today

    April 15, 2026

    The Top AI Apps Consumers Are Actually Using

    April 14, 2026

    Wall Street banks break records as Iran war drives trading boom

    April 14, 2026

    Subscribe to Updates

    Please enable JavaScript in your browser to complete this form.
    Loading

    At Money Mechanics, we believe money shouldn’t be confusing. It should be empowering. Whether you’re buried in debt, cautious about investing, or simply overwhelmed by financial jargon—we’re here to guide you every step of the way.

    Facebook X (Twitter) Instagram Pinterest YouTube
    Links
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Resources
    • Breaking News
    • Economy & Policy
    • Finance Tools
    • Fintech & Apps
    • Guides & How-To
    Get Informed

    Subscribe to Updates

    Please enable JavaScript in your browser to complete this form.
    Loading
    Copyright© 2025 TheMoneyMechanics All Rights Reserved.
    • Breaking News
    • Economy & Policy
    • Finance Tools
    • Fintech & Apps
    • Guides & How-To

    Type above and press Enter to search. Press Esc to cancel.